Marcello Tiseo

26PUBLICATIONS
119CO-AUTHORS
Predictive and prognostic markersLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jul 14, 2026
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

|Jun 12, 2026
Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020).

|Jan 12, 2026
Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report.

Margherita Agostini, Samuele Compagno, Francesca Sperandi

|Nov 17, 2025
Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy.

Fabiana Letizia Cecere, Ettore D'Argento, Francesco Gelsomino

|Aug 27, 2025
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci, Hui Li, Alessandro Di Federico

|Dec 05, 2024
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Alessandro Di Federico, Stefania Angelicola, Mariateresa Frascino

Pageof 5

Frequent Collaborators

9 joint publications

Alessandro Di Federico

9 joint publications

Andrea De Giglio

4 joint publications

Giuseppe Lamberti

4 joint publications

Arianna Palladini